NCT00198380 2024-03-08
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
Clinical Trials
100 trialsNCT01185158 2023-11-29
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
University of Chicago
Phase 2 Completed
NCT01833572 2023-07-12
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)
Fudan University
Phase 2 Completed
NCT01185171 2023-05-11
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
Phase 2 Completed
NCT02447419 2022-06-15
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
Samsung Medical Center
Phase 2 Completed
NCT03170180 2022-06-15
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT01556191 2021-01-08
LADIE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT00025116 2020-04-06
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT01933347 2020-02-06
Third-line Treatment of Gefitinib in NSCLC Patients
Guangdong Association of Clinical Trials
Phase 2 Completed
NCT02976116 2019-11-15
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT00014183 2019-11-07
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT01469000 2019-09-10
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT00126555 2019-08-30
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02179671 2019-08-02
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT00027690 2019-07-23
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00025675 2018-06-26
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01864681 2018-06-20
CGMT
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT00215202 2018-05-17
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00509002 2017-11-24
Iressa Study in Patients With Salivary Gland Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT00188617 2017-03-14
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
University Health Network, Toronto
Phase 2 Completed
NCT00062062 2016-12-14
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00100945 2016-12-13
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00059722 2016-08-24
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Sanofi
Phase 2 Completed
NCT00519077 2016-07-01
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Completed
NCT01530334 2016-02-23
ICARUS
AstraZeneca
Phase 2 Completed
NCT01783834 2016-02-11
Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
Gachon University Gil Medical Center
Phase 2 Completed
NCT00588445 2016-01-22
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00177242 2016-01-18
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00268346 2016-01-05
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00229697 2015-10-05
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
AstraZeneca
Phase 2 Completed
NCT00258323 2015-09-30
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00054691 2015-03-13
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01498562 2014-12-02
DATE
Yonsei University
Phase 2 Completed
NCT00077025 2014-07-16
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00057941 2014-05-12
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00130702 2014-05-01
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01017679 2013-12-10
Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
Sun Yat-sen University
Phase 2 Completed
NCT00066378 2013-10-24
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00015964 2013-09-05
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
University of Chicago
Phase 2 Completed
NCT00012337 2013-06-24
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025350 2013-06-24
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016991 2013-06-20
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Duke University
Phase 2 Completed
NCT00049556 2013-06-20
Gefitinib in Treating Patients With Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00075439 2013-06-04
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025142 2013-05-15
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00411047 2013-05-14
Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 2 Completed